137 related articles for article (PubMed ID: 37793052)
1. Association between antihyperlipidemic agents and the risk of chronic periodontitis in patients with hyperlipidemia: A population-based retrospective cohort study in Taiwan.
Wang AY; Lin GL; Keller JJ; Wang LH
J Periodontol; 2024 May; 95(5):483-493. PubMed ID: 37793052
[TBL] [Abstract][Full Text] [Related]
2. Association Between Use of Antihyperlipidemic Agents and Chronic Obstructive Pulmonary Disease in Patients with Hyperlipidemia: A Population-Based Retrospective Cohort Study.
Lei YF; Lin HC; Lin HL; Uang YS; Cheng HW; Wang LH
Int J Chron Obstruct Pulmon Dis; 2020; 15():2573-2581. PubMed ID: 33116474
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy and safety of combined statin-fenofibrates therapy compared with monotherapy in patients with mixed hyperlipidemia and high risk of coronary heart disease].
Kłosiewicz-Latoszek L; Respondek W; Białobrzeska-Paluszkiewicz J; Grzybowska B; Jakóbisiak-Ostasz B; Stolarska I
Pol Merkur Lekarski; 2003 Jul; 15(85):42-6. PubMed ID: 14593958
[TBL] [Abstract][Full Text] [Related]
4. Pharmacoepidemiology safety study of fibrate and statin concomitant therapy.
Enger C; Gately R; Ming EE; Niemcryk SJ; Williams L; McAfee AT
Am J Cardiol; 2010 Dec; 106(11):1594-601. PubMed ID: 21094360
[TBL] [Abstract][Full Text] [Related]
5. Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction.
Tenenbaum A; Fisman EZ
Cardiovasc Diabetol; 2012 Oct; 11():125. PubMed ID: 23057687
[TBL] [Abstract][Full Text] [Related]
6. Use of lipid-lowering agents is not associated with improved outcomes for tuberculosis patients on standard-course therapy: A population-based cohort study.
Chen YT; Kuo SC; Chao PW; Chang YY
PLoS One; 2019; 14(1):e0210479. PubMed ID: 30633771
[TBL] [Abstract][Full Text] [Related]
7. Comparison of pleiotropic effects of statins vs fibrates on laboratory parameters in patients with dyslipidemia: A retrospective cohort study.
Takeuchi S; Takahashi Y; Asai S
Medicine (Baltimore); 2020 Dec; 99(50):e23427. PubMed ID: 33327270
[TBL] [Abstract][Full Text] [Related]
8. Statin-fibrate combination therapy.
Shek A; Ferrill MJ
Ann Pharmacother; 2001; 35(7-8):908-17. PubMed ID: 11485144
[TBL] [Abstract][Full Text] [Related]
9. Statin reduces mortality and morbidity in systemic lupus erythematosus patients with hyperlipidemia: A nationwide population-based cohort study.
Yu HH; Chen PC; Yang YH; Wang LC; Lee JH; Lin YT; Chiang BL
Atherosclerosis; 2015 Nov; 243(1):11-8. PubMed ID: 26342937
[TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness of statin plus fibrate combination therapy and statin monotherapy in patients with type 2 diabetes: use of propensity-score and instrumental variable methods to adjust for treatment-selection bias.
Suh HS; Hay JW; Johnson KA; Doctor JN
Pharmacoepidemiol Drug Saf; 2012 May; 21(5):470-84. PubMed ID: 22461130
[TBL] [Abstract][Full Text] [Related]
11. The effect of statins on the occurrence of peptic ulcer.
Feng A; Chuang E; Wu SH; Wang JC; Chang SN; Lin CL; Kao CH
Eur J Intern Med; 2015 Nov; 26(9):731-5. PubMed ID: 26226858
[TBL] [Abstract][Full Text] [Related]
12. DPP-4 Inhibitors in Combination with Lipid-Lowering Agents and Risk of Serious Muscular Injury: A Nested Case-Control Study in a Nationwide Cohort of Patients with Type 2 Diabetes Mellitus.
Pariente A; Labat V; Mansiaux Y; Salvo F; Bégaud B; Raschi E; Faillie JL; Létinier L; Bezin J
Drug Saf; 2020 Aug; 43(8):767-774. PubMed ID: 32306223
[TBL] [Abstract][Full Text] [Related]
13. Statins Reduce the Risk of Cirrhosis and Its Decompensation in Chronic Hepatitis B Patients: A Nationwide Cohort Study.
Huang YW; Lee CL; Yang SS; Fu SC; Chen YY; Wang TC; Hu JT; Chen DS
Am J Gastroenterol; 2016 Jul; 111(7):976-85. PubMed ID: 27166128
[TBL] [Abstract][Full Text] [Related]
14. Effects of Statin Therapy on the Risk of Intracerebral Hemorrhage in Korean Patients with Hyperlipidemia.
Jung M; Lee S
Pharmacotherapy; 2019 Feb; 39(2):129-139. PubMed ID: 30585646
[TBL] [Abstract][Full Text] [Related]
15. 2017 Taiwan lipid guidelines for high risk patients.
Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
[TBL] [Abstract][Full Text] [Related]
16. Hyperlipidemia and Statins Use for the Risk of New Diagnosed Sarcopenia in Patients with Chronic Kidney: A Population-Based Study.
Lin MH; Chiu SY; Chang PH; Lai YL; Chen PC; Ho WC
Int J Environ Res Public Health; 2020 Feb; 17(5):. PubMed ID: 32110901
[No Abstract] [Full Text] [Related]
17. Physician variation in the de-adoption of ineffective statin and fibrate therapy.
Everhart A; Desai NR; Dowd B; Herrin J; Higuera L; Jeffery MM; Jena AB; Ross JS; Shah ND; Smith LB; Karaca-Mandic P
Health Serv Res; 2021 Oct; 56(5):919-931. PubMed ID: 33569804
[TBL] [Abstract][Full Text] [Related]
18. Use of fibrates in clinical practice: Queensland Lipid Group consensus recommendations.
Hamilton-Craig I; Kostner KM; Woodhouse S; Colquhoun D
Int J Evid Based Healthc; 2012 Sep; 10(3):181-90. PubMed ID: 22925614
[TBL] [Abstract][Full Text] [Related]
19. Do lipids and apolipoproteins predict coronary heart disease under statin and fibrate therapy in the primary prevention setting in community-dwelling elderly subjects? The 3C Study.
Straczek C; Tafflet M; Barberger-Gateau P; Bertrand M; Dupuy AM; Ducimetière P; Empana JP
Atherosclerosis; 2011 Feb; 214(2):426-31. PubMed ID: 21129746
[TBL] [Abstract][Full Text] [Related]
20. Fibrate and the risk of cardiovascular disease among moderate chronic kidney disease patients with primary hypertriglyceridemia.
Yen CL; Fan PC; Lee CC; Chen JJ; Chen CY; Tu YR; Chu PH; Hsiao CC; Chen YC; Chang CH
Front Endocrinol (Lausanne); 2024; 15():1333553. PubMed ID: 38414823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
